Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy.
Root JL, Desai PN, Ly C, Wang B, Jelloul FZ, Zhou J, Mackay S, Alfayez M, Matthews J, Pierce S, Reville PK, Daver N, Abbas HA. Root JL, et al. Among authors: reville pk. Cancer Res Commun. 2024 Mar 6;4(3):671-681. doi: 10.1158/2767-9764.CRC-23-0402. Cancer Res Commun. 2024. PMID: 38391202 Free PMC article.
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. Erbe AK, et al. Among authors: reville pk. Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017. Front Immunol. 2017. PMID: 28659916 Free PMC article.
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Reville PK, et al. Blood Cancer J. 2021 Mar 17;11(3):60. doi: 10.1038/s41408-021-00453-z. Blood Cancer J. 2021. PMID: 33731681 Free PMC article. Clinical Trial. No abstract available.
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: reville pk. Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7. Lancet Haematol. 2021. PMID: 34329576 Free PMC article. Clinical Trial.
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Abbas HA, et al. Among authors: reville pk. Leuk Lymphoma. 2021 Dec;62(14):3402-3410. doi: 10.1080/10428194.2021.1961235. Epub 2021 Aug 12. Leuk Lymphoma. 2021. PMID: 34380367 Free PMC article.
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, Wang L, Daver N, Futreal A. Abbas HA, et al. Among authors: reville pk. Nat Commun. 2021 Oct 18;12(1):6071. doi: 10.1038/s41467-021-26282-z. Nat Commun. 2021. PMID: 34663807 Free PMC article.
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Reville PK, et al. Am J Hematol. 2022 Mar 1;97(3):329-337. doi: 10.1002/ajh.26451. Epub 2022 Jan 8. Am J Hematol. 2022. PMID: 34981570 Free PMC article.
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Lachowiez CA, et al. Among authors: reville pk. Lancet Haematol. 2022 May;9(5):e350-e360. doi: 10.1016/S2352-3026(22)00076-X. Lancet Haematol. 2022. PMID: 35483396 Free PMC article. Clinical Trial.
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Yilmaz M, et al. Blood Cancer J. 2022 May 2;12(5):77. doi: 10.1038/s41408-022-00670-0. Blood Cancer J. 2022. PMID: 35501304 Free PMC article.
25 results